Okogen, Inc., a clinical-stage biotechnology company focused on developing therapies for infectious diseases, announced that the Central Drugs Standard Control Organisation (CDSCO), India's national drug regulatory authority, has authorized the EMERALD study, a Phase 1/2 clinical trial evaluating Treyegen (OKG-0303) for the treatment of acute infectious conjunctivitis. The authorization marks a significant step forward for the company's lead ophthalmology program and its broader host-directed antiviral platform.
The EMERALD study will enroll more than 300 patients and is designed to evaluate safety, pharmacokinetics, virologic and microbiologic activity, and clinical efficacy. Data from the trial are expected later this year. This is the first clinical evaluation of Treyegen in patients with acute infectious conjunctivitis, a common ocular condition that can be caused by both viruses and bacteria.
Treyegen is an investigational ophthalmic therapy that combines three active ingredients into a single formulation: ranpirnase, a host-directed antiviral; tobramycin, a broad-spectrum antibacterial agent; and oxymetazoline, which reduces ocular redness. Okogen believes this differentiated approach could simplify treatment decisions by providing physicians with a comprehensive therapeutic option for patients presenting with acute infectious conjunctivitis, rather than requiring them to distinguish between viral and bacterial causes before prescribing treatment.
The CDSCO authorization advances Okogen's strategy of using ophthalmology as the lead clinical proving ground for its ranpirnase-based platform. The company is developing ranpirnase therapies across four therapeutic pillars: ophthalmology, medical countermeasures, systemic antivirals, and dermatology. The goal is to apply clinical insights, formulation expertise, and manufacturing capabilities from the ophthalmology program across a broader portfolio of antiviral therapies.
For readers, this announcement signals potential progress toward a new treatment option for a condition that affects millions of people worldwide. Acute infectious conjunctivitis, often called pink eye, is highly contagious and can spread rapidly in schools, workplaces, and communities. A single therapy that addresses both viral and bacterial forms could reduce diagnostic uncertainty, streamline patient care, and potentially curb inappropriate antibiotic use. For the biotechnology and pharmaceutical industries, the EMERALD study represents a test of the host-directed antiviral approach, which aims to treat infections by targeting the host's cellular machinery rather than the pathogen itself. If successful, this platform could be applied to other infectious diseases, including those with limited treatment options.
The trial's data, expected later this year, will provide the first clinical evidence of Treyegen's safety and efficacy in patients. Positive results could position Okogen for later-stage trials and potential regulatory submissions. For more information about the EMERALD study, click here. Additional details about Okogen and its pipeline are available at www.okogen.com.
Okogen, Inc. is a clinical-stage biotechnology company developing a broad-spectrum, host-directed antiviral platform built around ranpirnase. The company is advancing ranpirnase-based therapies across ophthalmology, medical countermeasures, systemic antivirals, and dermatology. The EMERALD study is the company's lead clinical program and is being conducted in India under CDSCO authorization. The trial will evaluate Treyegen in more than 300 patients, with data expected later this year. The company's development strategy positions ophthalmology as the lead clinical proving ground for the platform, with the goal of applying clinical insights, formulation expertise, and manufacturing capabilities across a broader portfolio of antiviral therapies.
